Ann W. Gramza

731 total citations
22 papers, 552 citations indexed

About

Ann W. Gramza is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Ann W. Gramza has authored 22 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in Ann W. Gramza's work include Thyroid Cancer Diagnosis and Treatment (11 papers), Lung Cancer Research Studies (5 papers) and Cancer Research and Treatments (3 papers). Ann W. Gramza is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (11 papers), Lung Cancer Research Studies (5 papers) and Cancer Research and Treatments (3 papers). Ann W. Gramza collaborates with scholars based in United States, Italy and Israel. Ann W. Gramza's co-authors include Christopher L. Corless, Michael C. Heinrich, Barbara Jarząb, Jai Balkissoon, Frank G. Ondrey, Julie Ann Sosa, Chandrasekhar Bal, Shanthi Marur, Rossella Elisei and Fadlo R. Khuri and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Ann W. Gramza

18 papers receiving 541 citations

Peers

Countries citing papers authored by Ann W. Gramza

Since Specialization

Citations

This map shows the geographic impact of Ann W. Gramza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann W. Gramza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann W. Gramza more than expected).

Fields of papers citing papers by Ann W. Gramza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann W. Gramza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann W. Gramza. The network helps show where Ann W. Gramza may publish in the future.

Co-authorship network of co-authors of Ann W. Gramza

This figure shows the co-authorship network connecting the top 25 collaborators of Ann W. Gramza. A scholar is included among the top collaborators of Ann W. Gramza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann W. Gramza. Ann W. Gramza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers 2025 ·Annals of Oncology ·Himisha Beltran, (unknown), Prantesh Jain, Erin L. Schenk, Rachel E. Sanborn, John A. Thompson, (unknown), Hirva Mamdani, Rahul Aggarwal, K. Nathan Sankar, (unknown), Vassiliki Karantza, Aiguo Wang, Ann W. Gramza, (unknown)	0
2	2792TiP A phase Ib/II study of gocatamig (MK-6070; HPN328) and ifinatamab deruxtecan for relapsed/refractory extensive-stage small cell lung cancer (ES-SCLC) 2025 ·Annals of Oncology ·Jair Bar, (unknown), (unknown), (unknown), (unknown), Christian Caglevic, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ryo Ariyasu, (unknown), (unknown), Vassiliki Karantza, (unknown), Ann W. Gramza, (unknown)	0
3	OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer 2024 ·Journal of Thoracic Oncology ·Noura J. Choudhury, Himisha Beltran, (unknown), Erin L. Schenk, Rachel E. Sanborn, Jonathan R. Thompson, Hirva Mamdani, (unknown), Rahul Aggarwal, Ann W. Gramza, Prantesh Jain	4
4	Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). 2024 ·Journal of Clinical Oncology ·Himisha Beltran, Afshin Dowlati, Prantesh Jain, Melissa L. Johnson, Rachel E. Sanborn, Jonathan R. Thompson, Hirva Mamdani, Erin L. Schenk, Rahul Aggarwal, K. Nathan Sankar, Ann W. Gramza, Banmeet S. Anand, Noura J. Choudhury	19
5	Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). 2024 ·Journal of Clinical Oncology ·Himisha Beltran, Melissa L. Johnson, Prantesh Jain, Erin L. Schenk, Rachel E. Sanborn, Jonathan R. Thompson, Afshin Dowlati, Hirva Mamdani, Rahul Aggarwal, Banmeet S. Anand, Ann W. Gramza, Noura J. Choudhury	18
6	656 A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression 2024 ·Regular and Young Investigator Award Abstracts ·Prantesh Jain, Alissa J. Cooper, Melissa L. Johnson, Erin L. Schenk, Rachel E. Sanborn, Jonathan R. Thompson, Hirva Mamdani, Afshin Dowlati, Rahul Aggarwal, K. Nathan Sankar, Ann W. Gramza, Himisha Beltran	0
7	Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). 2023 ·Journal of Clinical Oncology ·Alain P. Algazi, William D. Smith, Justine Y. Bruce, Dong M. Shin, Ann W. Gramza, (unknown), (unknown), Krzysztof Misiukiewicz, (unknown), Jean S. Campbell, Robert H. Pierce	0
8	Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). 2021 ·Journal of Clinical Oncology ·Alain P. Algazi, (unknown), William P. Smith, Timothy J. Panella, Dong M. Shin, Justine Y. Bruce, (unknown), Jean S. Campbell, Lauren Abell, (unknown), (unknown), Robert H. Pierce, Ann W. Gramza	1
9	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer 2020 ·Frontiers in Endocrinology ·Jaydira Del Rivero, Renee N. Donahue, Jennifer L. Marté, Ann W. Gramza, Marijo Bilušić, Myrna Rauckhorst, Lisa M. Cordes, Maria J. Merino, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi A. Madan	15
10	Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer 2018 ·The Oncologist ·(unknown), Maureen Edgerly, (unknown), Ravi A. Madan, Sanjeeve Balasubramaniam, Tito Fojo, Ann W. Gramza	16
11	Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial 2013 ·The Journal of Clinical Endocrinology & Metabolism ·Robert C. Smallridge, John A. Copland, Marcia S. Brose, J. Trad Wadsworth, Yariv Houvras, Michael E. Menefee, Keith C. Bible, Manisha H. Shah, Ann W. Gramza, Joshua Klopper, Laura A. Marlow, Michael G. Heckman, Reinhard von Roemeling	93
12	Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma 2013 ·Thyroid ·Julie Ann Sosa, Rossella Elisei, Barbara Jarząb, Jai Balkissoon, (unknown), Chandrasekhar Bal, Shanthi Marur, Ann W. Gramza, R. Ben Yosef, Barbara J. Gitlitz, Bryan R. Haugen, Frank G. Ondrey, Charles Lu, (unknown), Fadlo R. Khuri, Lisa Licitra, Scot C. Remick	116
13	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer 2012 ·Surgery ·Julie Ann Sosa, Jai Balkissoon, (unknown), P. Langecker, Rossella Elisei, Barbara Jarząb, Chandrasekhar Bal, Shanthi Marur, Ann W. Gramza, Frank G. Ondrey	32
14	Thyroid cancer bone metastases and high morbidity rates 2012 ·Nature Reviews Endocrinology ·Ann W. Gramza, Electron Kebebew	3
15	Abstract 1278: Phase 1 study of CS-7017, an oral PPAR-γ agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer 2011 ·Cancer Research ·Robert C. Smallridge, John A. Copland, Marcia S. Brose, J. Trad Wadsworth, Yariv Houvras, Keith C. Bible, Manisha H. Shah, Ann W. Gramza, Joshua Klopper, Reinhard von Roemeling	1
16	Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. 2011 ·Journal of Clinical Oncology ·Ann W. Gramza, Samuel A. Wells, Sanjeeve Balasubramaniam, Antonio Tito Fojo	3
17	A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. 2011 ·Journal of Clinical Oncology ·Julie Ann Sosa, Rossella Elisei, Barbara Jarząb, Chandrasekhar Bal, H. Koussis, Ann W. Gramza, Rami Ben‐Yosef, Barbara J. Gitlitz, Bryan R. Haugen, (unknown), Fadlo R. Khuri, Lisa Licitra, S. C. Remick, Shanthi Marur, Charles Lu, Frank G. Ondrey, (unknown), Jai Balkissoon	31
18	Abstract 4547: Treatment of human medullary thyroid carcinoma (MTC) with either proteasome (Pr) or histone deacetylase (HDAC) inhibitors leads to a fall in RET mRNA levels and, in turn, a decrease in RET protein expression providing alternate strategies to reduce RET expression in a tyrosine-kinase driven disease 2011 ·Cancer Research ·Marianne S. Poruchynsky, Ann W. Gramza, Samuel A. Wells, Tito Fojo	2
19	Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer. 2010 ·Journal of Clinical Oncology ·Ann W. Gramza, Jennifer Patterson, (unknown), (unknown), Steven G. Wise, Declan Flynn	1
20	Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors 2009 ·Clinical Cancer Research ·Ann W. Gramza, Christopher L. Corless, Michael C. Heinrich	176

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact